{"id":"https://openalex.org/W2005140078","doi":"https://doi.org/10.1377/hlthaff.2014.0511","title":"Specialty Medications: Traditional And Novel Tools Can Address Rising Spending On These Costly Drugs","display_name":"Specialty Medications: Traditional And Novel Tools Can Address Rising Spending On These Costly Drugs","alternate_titles":[],"publication_year":2014,"publication_date":"2014-10-01","ids":{"openalex":"https://openalex.org/W2005140078","doi":"https://doi.org/10.1377/hlthaff.2014.0511","mag":"2005140078","pmid":"https://pubmed.ncbi.nlm.nih.gov/25288417"},"language":"en","primary_location":{"id":"doi:10.1377/hlthaff.2014.0511","doi":"https://doi.org/10.1377/hlthaff.2014.0511","is_oa":false,"landing_page_url":"https://doi.org/10.1377/hlthaff.2014.0511","pdf_url":null,"source":{"id":"https://openalex.org/S4210185023","display_name":"Health Affairs","issn_l":"0278-2715","issn":["0278-2715","1544-5208","2694-233X"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["anvur-scientific","dongbi-a","doyens","fnege-2","jufo-2","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315983","host_organization_name":"Project HOPE","host_organization_lineage":["https://openalex.org/P4310315983"],"host_organization_lineage_names":["Project HOPE"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Health Affairs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2005140078"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012311792","display_name":"Alan M. Lotvin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115892","display_name":"CVS Health (United States)","ror":"https://ror.org/02jfw4p72","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115892"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan M. Lotvin","raw_affiliation_strings":["Alan M. Lotvin is executive vice president for specialty pharmacy at CVS Caremark, in Woonsocket, Rhode Island"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alan M. Lotvin is executive vice president for specialty pharmacy at CVS Caremark, in Woonsocket, Rhode Island","institution_ids":["https://openalex.org/I4210115892"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060167116","display_name":"William H. Shrank","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115892","display_name":"CVS Health (United States)","ror":"https://ror.org/02jfw4p72","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115892"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William H. Shrank","raw_affiliation_strings":["William H. Shrank ( ) is chief scientific officer and chief medical officer of provider innovation at CVS Caremark","William H. Shrank (#R# ) is chief scientific officer and chief medical officer of provider innovation at CVS Caremark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"William H. Shrank ( ) is chief scientific officer and chief medical officer of provider innovation at CVS Caremark","institution_ids":["https://openalex.org/I4210115892"]},{"raw_affiliation_string":"William H. Shrank (#R# ) is chief scientific officer and chief medical officer of provider innovation at CVS Caremark","institution_ids":["https://openalex.org/I4210115892"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014608863","display_name":"Surya C. Singh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115892","display_name":"CVS Health (United States)","ror":"https://ror.org/02jfw4p72","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115892"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Surya C. Singh","raw_affiliation_strings":["Surya C. Singh is corporate vice president for specialty client solutions and trend management at CVS Caremark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Surya C. Singh is corporate vice president for specialty client solutions and trend management at CVS Caremark","institution_ids":["https://openalex.org/I4210115892"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061773942","display_name":"Benjamin P. Falit","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin P. Falit","raw_affiliation_strings":["Benjamin P. Falit is a resident physician in the Harvard Radiation Oncology Program at Brigham and Women\u2019s Hospital, in Boston, Massachusetts, and a consultant to CVS Caremark on matters related to oncology and specialty pharmacy strategy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Benjamin P. Falit is a resident physician in the Harvard Radiation Oncology Program at Brigham and Women\u2019s Hospital, in Boston, Massachusetts, and a consultant to CVS Caremark on matters related to oncology and specialty pharmacy strategy","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103949633","display_name":"Troyen A. Brennan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115892","display_name":"CVS Health (United States)","ror":"https://ror.org/02jfw4p72","country_code":"US","type":"company","lineage":["https://openalex.org/I4210115892"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Troyen A. Brennan","raw_affiliation_strings":["Troyen A. Brennan is chief medical officer at CVS Caremark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Troyen A. Brennan is chief medical officer at CVS Caremark","institution_ids":["https://openalex.org/I4210115892"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":16.7309,"has_fulltext":false,"cited_by_count":62,"citation_normalized_percentile":{"value":0.98862656,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"33","issue":"10","first_page":"1736","last_page":"1744"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9843999743461609,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.006099999882280827,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10391","display_name":"Healthcare Policy and Management","score":0.00430000014603138,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/specialty-medications","display_name":"specialty medications","score":0.9990000128746033},{"id":"https://openalex.org/keywords/prescription-drug-costs","display_name":"prescription drug costs","score":0.7080000042915344},{"id":"https://openalex.org/keywords/prior-authorization","display_name":"prior authorization","score":0.7850000262260437},{"id":"https://openalex.org/keywords/step-therapy","display_name":"step therapy","score":0.9980000257492065},{"id":"https://openalex.org/keywords/drug-delivery-systems","display_name":"drug delivery systems","score":0.6240000128746033},{"id":"https://openalex.org/keywords/drug-development-costs","display_name":"drug development costs","score":0.6399999856948853},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.3970000147819519}],"concepts":[{"id":"https://openalex.org/C20387591","wikidata":"https://www.wikidata.org/wiki/Q930752","display_name":"Specialty","level":2,"score":0.8906952142715454},{"id":"https://openalex.org/C2779598192","wikidata":"https://www.wikidata.org/wiki/Q17514788","display_name":"Prior authorization","level":2,"score":0.7629462480545044},{"id":"https://openalex.org/C100406419","wikidata":"https://www.wikidata.org/wiki/Q3543802","display_name":"Formulary","level":2,"score":0.7509239315986633},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.6717250347137451},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.541770875453949},{"id":"https://openalex.org/C2780062483","wikidata":"https://www.wikidata.org/wiki/Q7902865","display_name":"Utilization management","level":3,"score":0.49940919876098633},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.465329110622406},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.30864569544792175},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.2982989251613617},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.17544978857040405},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.1499553918838501},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.14074960350990295}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001688","descriptor_name":"Biological Products","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D003363","descriptor_name":"Cost Control","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D003363","descriptor_name":"Cost Control","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D012051","descriptor_name":"Reimbursement Mechanisms","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016527","descriptor_name":"Drug Costs","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D017048","descriptor_name":"Health Care Costs","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D055553","descriptor_name":"Prescription Drugs","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1377/hlthaff.2014.0511","doi":"https://doi.org/10.1377/hlthaff.2014.0511","is_oa":false,"landing_page_url":"https://doi.org/10.1377/hlthaff.2014.0511","pdf_url":null,"source":{"id":"https://openalex.org/S4210185023","display_name":"Health Affairs","issn_l":"0278-2715","issn":["0278-2715","1544-5208","2694-233X"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["anvur-scientific","dongbi-a","doyens","fnege-2","jufo-2","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315983","host_organization_name":"Project HOPE","host_organization_lineage":["https://openalex.org/P4310315983"],"host_organization_lineage_names":["Project HOPE"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Health Affairs","raw_type":"journal-article"},{"id":"pmid:25288417","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25288417","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Health affairs (Project Hope)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1968741068","https://openalex.org/W1971875890","https://openalex.org/W2047372585","https://openalex.org/W2054731661","https://openalex.org/W2062260935","https://openalex.org/W2063223428","https://openalex.org/W2067032911","https://openalex.org/W2083585578","https://openalex.org/W2087239182","https://openalex.org/W2094905849","https://openalex.org/W2118112823","https://openalex.org/W2118443399","https://openalex.org/W2131697358","https://openalex.org/W2132047269","https://openalex.org/W2136382580","https://openalex.org/W2145826431","https://openalex.org/W2156864608","https://openalex.org/W2164521956","https://openalex.org/W2316170888","https://openalex.org/W2325970073","https://openalex.org/W3121503766","https://openalex.org/W4248299881"],"related_works":["https://openalex.org/W2791575855","https://openalex.org/W4368361529","https://openalex.org/W7220601364","https://openalex.org/W173046137","https://openalex.org/W53781188","https://openalex.org/W1872645650","https://openalex.org/W3108577062","https://openalex.org/W2142303512","https://openalex.org/W2063050425","https://openalex.org/W2277913221"],"abstract_inverted_index":{"Spending":[0],"on":[1],"specialty":[2,88,95,115,135],"medications,":[3],"which":[4],"represented":[5],"a":[6,73,141],"small":[7],"proportion":[8],"of":[9,16,37,52,56,62,69,86,94,110,114,143],"US":[10],"pharmacy":[11,40],"spending":[12,41],"at":[13,158],"the":[14,45,49,59,66,84,87,91,107,111,162],"beginning":[15],"this":[17,53,80],"decade,":[18],"is":[19,28],"growing":[20],"by":[21,42],"more":[22],"than":[23],"15":[24],"percent":[25],"annually.":[26],"It":[27],"expected":[29],"to":[30,121,139],"account":[31],"for":[32,48,134,167],"approximately":[33],"half":[34],"($235":[35],"billion)":[36],"total":[38],"annual":[39],"2018.":[43],"Among":[44],"numerous":[46],"reasons":[47],"high":[50,67],"cost":[51,68],"heterogeneous":[54],"group":[55],"medications":[57,116,136],"are":[58],"increasing":[60],"size":[61],"target":[63],"patient":[64],"populations,":[65],"drug":[70],"development,":[71],"and":[72,75,98,102,124,132,145,161],"complex":[74],"uncoordinated":[76],"delivery":[77],"system.":[78],"In":[79],"article":[81],"we":[82],"describe":[83],"evolution":[85],"market,":[89],"characterize":[90],"current":[92],"state":[93],"medication":[96],"use,":[97],"articulate":[99],"key":[100],"challenges":[101],"potential":[103,108],"solutions.":[104],"Fully":[105],"realizing":[106],"value":[109],"expanding":[112],"universe":[113],"will":[117,137],"require":[118],"collaborative":[119],"efforts":[120],"reduce":[122],"waste":[123],"promote":[125],"value.":[126],"Those":[127],"who":[128],"prescribe,":[129],"dispense,":[130],"deliver,":[131],"pay":[133],"need":[138],"employ":[140],"combination":[142],"traditional":[144],"novel":[146],"management":[147],"approaches,":[148],"such":[149],"as":[150],"prior":[151],"authorization,":[152],"step":[153],"therapy,":[154],"tiered":[155],"formularies,":[156],"administration":[157],"lower-cost":[159],"sites,":[160],"unique":[163],"tools":[164],"being":[165],"developed":[166],"cancer":[168],"medications.":[169]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2005140078","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":13},{"year":2015,"cited_by_count":5}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
